Vaccinex, Inc. (VCNX) — SEC Filings
Vaccinex, Inc. (VCNX) — 38 SEC filings. Latest: 10-K (Apr 15, 2025). Includes 21 8-K, 5 SC 13D/A, 3 10-Q.
View Vaccinex, Inc. on SEC EDGAR
Overview
Vaccinex, Inc. (VCNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 19, 2025: Vaccinex, Inc. filed an 8-K on March 19, 2025, reporting changes effective March 18, 2025. The filing covers the departure and election of directors, appointment of officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of the
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Vaccinex, Inc. is neutral.
Filing Type Overview
Vaccinex, Inc. (VCNX) has filed 2 10-K, 21 8-K, 5 SC 13D/A, 2 SC 13G, 3 10-Q, 1 10-K/A, 2 DEF 14A, 1 8-K/A, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of VCNX's 34 recent filings, 4 were flagged as high-risk, 17 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Maurice Zauderer
- Dr. Christopher J. Wagner
- Dr. Paul J. P. Ryan
- Albert D. Friedberg
- Thomas J. Rice
- Dr. Maurice Zauderer
Industry Context
Vaccinex, Inc. operates in the pharmaceutical preparations industry, specifically focusing on drug development.
Top Tags
amendment (6) · 8-K (5) · delisting (4) · 8-k (4) · sec-filing (4) · material-agreement (4) · financials (4) · corporate-governance (4) · management-change (3) · ownership-change (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| IRS Employer Identification No. | 16-1603202 | Identifies the company for tax purposes. |
| Standard Industrial Classification | 2834 | Indicates the company operates in Pharmaceutical Preparations. |
| SEC File Number | 001-38624 | Identifies the company's filing with the SEC. |
| Filing Amendment | Amendment No. 6 | Indicates this is a subsequent update to the original filing. |
| Filing Date | November 14, 2024 | The date of the event requiring this filing. |
| Commission File Number | 001-38624 | Identifies the company's SEC filing history |
| Reporting Period End Date | 20240930 | This is the end date for the Q3 2024 financial reporting. |
| IRS Number | 161603202 | Company's Employer Identification Number |
| Fiscal Year End | 1231 | Indicates the end of the company's annual accounting period. |
| Amendment Number | 11 | Indicates this is the eleventh update to the filing. |
| Ownership Stake | 5.0% | Friedberg Global-Macro Hedge Fund Ltd.'s beneficial ownership of VaccinEx, Inc. common stock as of August 1, 2024. |
| Number of Shares | 1,000,000 | Shares of VaccinEx, Inc. common stock beneficially owned by Friedberg Global-Macro Hedge Fund Ltd. |
| Period End Date | 2024-03-31 | CONFORMED PERIOD OF REPORT |
| SIC Code | 2834 | STANDARD INDUSTRIAL CLASSIFICATION |
| Value | 105,337 | FILING VALUES |
Forward-Looking Statements
- {"claim":"Point72 Asset Management, L.P. may increase its stake in Vaccinex, Inc. through warrant exercise.","entity":"Point72 Asset Management, L.P.","targetDate":"Within 12 months","confidence":"medium"}
- {"claim":"Vaccinex, Inc.'s stock price could see increased volatility due to institutional interest.","entity":"VACCINEX, INC.","targetDate":"Within 6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vaccinex, Inc. (VCNX)?
Vaccinex, Inc. has 38 recent SEC filings from Jan 2024 to Apr 2025, including 21 8-K, 5 SC 13D/A, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VCNX filings?
Across 38 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vaccinex, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vaccinex, Inc. (VCNX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vaccinex, Inc.?
Key financial highlights from Vaccinex, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VCNX?
The investment thesis for VCNX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vaccinex, Inc.?
Key executives identified across Vaccinex, Inc.'s filings include Maurice Zauderer, Dr. Christopher J. Wagner, Dr. Paul J. P. Ryan, Albert D. Friedberg, Thomas J. Rice and 1 others.
What are the main risk factors for Vaccinex, Inc. stock?
Of VCNX's 34 assessed filings, 4 were flagged high-risk, 17 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Vaccinex, Inc.?
Recent forward-looking statements from Vaccinex, Inc. include guidance on {"claim":"Point72 Asset Management, L.P. may increase its stake in Vaccinex, Inc. through warrant exercise.","entity":"P and 1 other predictions.